With the advent of the WTO product patent regime, the Indian pharmaceutical industry will no longer be able to introduce new molecules into the market within 2 to 5 years of the innovator companies introducing them abroad. The limitations of the Indian pharmaceutical industry with respect to its new product development capabilities could lead to stagnation, or even an erosion of domestic market shares for Indian firms.
To counter the challenges of the immediate future, penetrating the patent-free US$ 200 billion segment of the vast and profitable markets of North America and Europe and enhancing reach in the global pharmaceutical market is perhaps the most pragmatic and lucrative option for Indian firms.
CII Gujarat and PharmAlliance are pleased to announce a seminar on Market Penetration and Regulatory Approvals in Europe and USA. The objective of this seminar is to provide a platform for the Indian Pharmaceutical Industry to interact with top-level industry and regulatory experts from India and abroad and gain an insight into penetrating these markets.
|
